MX384021B - Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. - Google Patents

Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.

Info

Publication number
MX384021B
MX384021B MX2016005710A MX2016005710A MX384021B MX 384021 B MX384021 B MX 384021B MX 2016005710 A MX2016005710 A MX 2016005710A MX 2016005710 A MX2016005710 A MX 2016005710A MX 384021 B MX384021 B MX 384021B
Authority
MX
Mexico
Prior art keywords
particles
compositions
methods
applications
ophthalmic
Prior art date
Application number
MX2016005710A
Other languages
English (en)
Spanish (es)
Other versions
MX2016005710A (es
Inventor
Alexey Popov
Elizabeth M Enlow
Hongming Chen
James Bourassa
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of MX2016005710A publication Critical patent/MX2016005710A/es
Publication of MX384021B publication Critical patent/MX384021B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2016005710A 2013-11-02 2014-10-31 Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones. MX384021B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/070,506 US9827191B2 (en) 2012-05-03 2013-11-02 Compositions and methods for ophthalmic and/or other applications
PCT/US2014/063373 WO2015066444A1 (en) 2013-11-02 2014-10-31 Compositions and methods for ophthalmic and/or other applications

Publications (2)

Publication Number Publication Date
MX2016005710A MX2016005710A (es) 2017-02-08
MX384021B true MX384021B (es) 2025-03-14

Family

ID=53005177

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016005710A MX384021B (es) 2013-11-02 2014-10-31 Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2021007794A MX2021007794A (es) 2013-11-02 2016-05-02 Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007794A MX2021007794A (es) 2013-11-02 2016-05-02 Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.

Country Status (8)

Country Link
US (8) US9827191B2 (enExample)
EP (1) EP3062796B1 (enExample)
JP (3) JP6751669B2 (enExample)
CN (3) CN111743879A (enExample)
AU (1) AU2014342097B2 (enExample)
CA (2) CA3135978A1 (enExample)
MX (2) MX384021B (enExample)
WO (1) WO2015066444A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) * 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10864219B2 (en) * 2012-05-03 2020-12-15 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US20180071215A1 (en) * 2013-12-18 2018-03-15 Massachusetts Institute Of Technology Core-shell particles for controlled release
HUE048564T2 (hu) 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
JP6846351B2 (ja) 2015-01-27 2021-03-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘膜表面における活性薬剤の増強された輸送のための低張ヒドロゲル製剤
KR101938284B1 (ko) * 2015-06-15 2019-01-15 주식회사 엘지화학 형광 복합체, 광전환 필름, 광전환 소자 및 이를 포함하는 디스플레이 장치
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
US11529309B2 (en) * 2016-04-29 2022-12-20 University Of Houston System Compositions, methods and kits for treating a contact lens
MX2018016046A (es) 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
HUE058271T2 (hu) 2016-09-13 2022-07-28 Kyowa Kirin Co Ltd Tivozanibot tartalmazó gyógyászati készítmény
WO2018053321A1 (en) * 2016-09-16 2018-03-22 Kala Pharmaceuticals, Inc. Particles, compositions, and methods for ophthalmic and/or other applications
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US20210177751A1 (en) * 2017-12-08 2021-06-17 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
KR20210013574A (ko) 2018-05-25 2021-02-04 클라우드브레이크 테라퓨틱스, 엘엘씨 안구 충혈 치료용 조성물 및 이를 사용하여 안구 충혈을 치료하는 방법
EP3841086B1 (en) 2018-08-20 2025-04-23 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
CN113365617B (zh) 2018-10-16 2025-12-23 乔治亚州立大学研究基金会股份有限公司 用于医学疾病治疗的一氧化碳前药
KR102261590B1 (ko) * 2019-01-11 2021-06-07 한국콜마주식회사 수용성 추출물이 흡수된 화장용 캡슐을 포함하는 화장료 조성물
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
EP3946297A4 (en) * 2019-04-01 2023-08-02 Emory University HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASE INHIBITORS AND THEIR USES IN THE TREATMENT OF CANCER
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
EP3976106A4 (en) * 2019-05-31 2023-01-11 DOSE Medical Corporation BIOERODABLE POLYESTER-POLYMER IMPLANTS AND ASSOCIATED METHODS OF USE
JP7569336B2 (ja) * 2019-06-11 2024-10-17 サイファイ エス．ピー．エー． マイクロエマルション組成物
WO2021071835A1 (en) * 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
US11426351B2 (en) * 2019-12-26 2022-08-30 Sunstar Inc. Process for producing a pharmaceutical composition containing micro particles
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
WO2021222913A1 (en) * 2020-04-30 2021-11-04 Koziol Jeffrey E Micro dosing of viral vaccines
EP4171544A4 (en) * 2020-06-26 2024-07-24 Purdue Research Foundation PHARMACEUTICAL FORMULATIONS OF GRISEOFULVINE FOR LONG-TERM EYE ADMINISTRATION
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
EP4213804A1 (en) * 2020-09-16 2023-07-26 Santen SAS Oil-in-water emulsions for intravitreal administration
CA3193488A1 (en) 2020-09-23 2022-03-31 Jason Allan Wiles Pharmaceutical compounds for the treatment of complement mediated disorders
WO2022081795A2 (en) * 2020-10-14 2022-04-21 University Of Maryland, Baltimore County On demand and long-term drug delivery from degradable nanocapsules
US12186512B2 (en) * 2020-10-26 2025-01-07 Christopher Green Treatment for dry eyes
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
US12102622B2 (en) 2021-02-10 2024-10-01 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
EP4422640A4 (en) * 2021-10-28 2025-11-19 Evofem Inc FAST-DISSOLVING VAGINAL FILM WITH CONTRACEPTIVE ACTION AND PREVENTION OF SEXUALLY TRANSMITTED INFECTION
US11679078B1 (en) 2022-03-08 2023-06-20 EternaTear, Inc. Ophthalmic formulations and related methods
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
JPWO2023191003A1 (enExample) * 2022-03-31 2023-10-05
US20230310380A1 (en) * 2022-04-05 2023-10-05 Alan Neil Glazier Methods, devices, and systems for treating lens protein aggregation diseases
WO2024072751A1 (en) * 2022-09-26 2024-04-04 The Methodist Hospital Microparticle formulations for intravenous therapy and methods for their manufacture and use
KR20240115650A (ko) * 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법
IL326320A (en) * 2023-08-03 2026-04-01 Arcum Vision Inc Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses
CN118141743A (zh) * 2024-02-07 2024-06-07 中山大学 一种眼部注射制剂及其应用
CN118717992B (zh) * 2024-07-17 2025-01-28 华中科技大学 补体因子c3作为结晶样视网膜色素变性治疗靶点的应用

Family Cites Families (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
CH671402A5 (enExample) 1985-10-02 1989-08-31 Sandoz Ag
GB8601100D0 (en) 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US5718921A (en) 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US4839343A (en) 1987-03-13 1989-06-13 Debiopharm, S.A. Preparation containing hexatriacontapeptides and methods of use
US4910225A (en) 1988-01-27 1990-03-20 Senju Pharmaceutical Co., Ltd. Locally administrable therapeutic composition for inflammatory disease
US4868274A (en) 1988-05-23 1989-09-19 Hoechst Celanese Corp. Polyanhydride from carboxy aryloxy alkanoic acid
US4999417A (en) 1989-03-30 1991-03-12 Nova Pharmaceutical Corporation Biodegradable polymer compositions
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5696298A (en) 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
DE69329594T2 (de) 1992-02-28 2001-05-31 Board Of Regents, The University Of Texas System Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5364884A (en) 1993-01-21 1994-11-15 Baylor College Of Medicine Arginine compounds as ocular hypotensive agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5534259A (en) 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
CA2167920A1 (en) 1993-07-23 1995-02-02 Abraham J. Domb Nonoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
EP0744940B1 (en) 1994-02-17 1998-11-11 MODI, Pankaj Drugs, vaccines and hormones in polylactide coated microspheres
GB9406094D0 (en) 1994-03-28 1994-05-18 Univ Nottingham And University Polymer microspheres and a method of production thereof
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5576311A (en) 1994-11-30 1996-11-19 Pharmos Corporation Cyclodextrins as suspending agents for pharmaceutical suspensions
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
DE19511322C2 (de) 1995-03-28 1999-09-02 Mann Gerhard Chem Pharm Fab Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
DE19614823A1 (de) 1996-04-15 1997-10-16 Mann Gerhard Chem Pharm Fab Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ZA9711732B (en) 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US6106819A (en) 1996-12-31 2000-08-22 Sucher; David F. Methods of treating headache and functional extraocular and intraocular myotendinitis
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5869130A (en) 1997-06-12 1999-02-09 Mac Dermid, Incorporated Process for improving the adhesion of polymeric materials to metal surfaces
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
US6165509A (en) 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6372246B1 (en) 1998-12-16 2002-04-16 Ortho-Mcneil Pharmaceutical, Inc. Polyethylene glycol coating for electrostatic dry deposition of pharmaceuticals
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20020068090A1 (en) 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
WO2001021154A2 (en) 1999-09-21 2001-03-29 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP2316490A3 (en) 2000-10-31 2012-02-01 PR Pharmaceuticals, Inc. Methods and compositions for enhanced delivery of bioactive molecules
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6703039B2 (en) 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
GB2370839A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
AU2002322289A1 (en) 2001-06-22 2003-01-08 Johns Hopkins University School Of Medicine Biodegradable polymer coompositions
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
US20050191359A1 (en) 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20090215735A1 (en) 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
AU2006220411B2 (en) 2002-03-20 2008-06-26 Alkermes, Inc. Inhalable Sustained Therapeutic Formulations
EP1511467A1 (en) 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
UA82323C2 (uk) 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
MXPA05003162A (es) 2002-09-26 2005-07-05 Yamanouchi Pharma Co Ltd Agentes mejoradores de absorbibilidad de droga.
DE10248619A1 (de) * 2002-10-18 2004-04-29 Bayer Ag Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden
JP2006516262A (ja) 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
WO2004060977A1 (en) 2002-12-30 2004-07-22 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
US7060299B2 (en) 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US20050266090A1 (en) 2003-04-29 2005-12-01 Ales Prokop Nanoparticular targeting and therapy
WO2005044224A2 (en) 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
US7842232B2 (en) 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
WO2005008876A2 (en) 2003-07-09 2005-01-27 Board Of Regents, The University Of Texas System Methods and systems for simultaneous multiple frequency voltage generation
US20050009910A1 (en) 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
WO2005014524A2 (en) 2003-08-07 2005-02-17 Wisconsin Alumni Research Foundation Amino thiol compounds and compositions for use in conjunction with cancer therapy
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
JP4820648B2 (ja) * 2003-12-02 2011-11-24 千寿製薬株式会社 ロテプレドノールエタボネート水性懸濁液剤
GB0328630D0 (en) 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
EP1701704A2 (en) 2003-12-31 2006-09-20 Pfizer Products Inc. Solid compositions of low-solubility drugs and poloxamers
WO2005072710A2 (en) 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CA2555335A1 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
US20050182039A1 (en) 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
AU2005229006B9 (en) 2004-03-25 2011-05-19 Bausch & Lomb Incorporated Use of loteprednol etabonate for the treatment of dry eye
US20060018949A1 (en) 2004-04-07 2006-01-26 Bausch & Lomb Incorporated Injectable biodegradable drug delivery system
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
JP2008513363A (ja) 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
CA2580659C (en) 2004-09-15 2013-02-26 Ivx Animal Health, Inc. Corticosteroid having low systemic absorption
US7495052B2 (en) 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
MX2007003968A (es) 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
WO2006044660A2 (en) 2004-10-14 2006-04-27 Vanderbilt University Functionalized solid lipid nanoparticles and methods of making and using same
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
WO2006062875A1 (en) 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
WO2006063249A2 (en) 2004-12-10 2006-06-15 Justin Hanes Functionalized poly (ether-anhydride) block copolymers
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20080003322A (ko) 2005-02-24 2008-01-07 엘란 파마 인터내셔널 리미티드 도세탁셀 및 이의 유사체의 나노입자 배합물
CA2600085A1 (en) 2005-03-09 2006-09-14 Toray Industries, Inc. Microparticle and pharmaceutical preparation
DE102005011786A1 (de) 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
SI1885336T1 (sl) 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US7893040B2 (en) 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP2009508936A (ja) 2005-09-20 2009-03-05 イッサム リサーチ ディベロップメント カンパニー 活性物質の標的化送達用ナノ粒子
US20070071756A1 (en) 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an agent to ameliorate inflammation
US20070093461A1 (en) 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
EP1968548A2 (en) 2005-12-02 2008-09-17 Elan Pharma International Limited Mometasone compositions and methods of making and using the same
US20090155182A1 (en) 2005-12-09 2009-06-18 Invitrogen Corporation Optical in vivo imaging contrast agents and methods of use
EP1962808B1 (en) * 2005-12-14 2010-09-29 F. Hoffmann-La Roche AG Hcv prodrug formulation
US7544371B2 (en) 2005-12-20 2009-06-09 Bausch + Lomb Incorporated Drug delivery systems
US20070149480A1 (en) 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007076358A1 (en) 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007084418A2 (en) 2006-01-13 2007-07-26 Surmodics, Inc. Microparticle containing matrices for drug delivery
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070218103A1 (en) 2006-03-15 2007-09-20 Bausch & Lomb Incorporated Rate controlled release of a pharmaceutical agent in a biodegradable device
US20070218104A1 (en) 2006-03-15 2007-09-20 Bausch & Lomb Incorporation Rate controlled release of a pharmaceutical agent in a biodegradable device
US20070231360A1 (en) 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20080166411A1 (en) 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
US20070249536A1 (en) 2006-04-25 2007-10-25 Ma Peter X Three-component polyanhydride copolymers and a method of forming the same
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US20080102128A1 (en) 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
MX2009001294A (es) 2006-08-04 2009-05-21 Ethypharm Sa Granulo y tableta que se desintegra por vía oral que comprende oxicodona.
JP2010502713A (ja) 2006-09-08 2010-01-28 ザ・ジョンズ・ホプキンス・ユニバーシティー 粘液を通る輸送を増強するための組成物および方法
WO2008033924A2 (en) 2006-09-12 2008-03-20 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US7579021B2 (en) 2006-09-27 2009-08-25 Bausch & Lomb Incorporated Drug delivery systems based on degradable cationic siloxanyl macromonomers
US8394488B2 (en) 2006-10-06 2013-03-12 Cordis Corporation Bioabsorbable device having composite structure for accelerating degradation
US8586556B2 (en) * 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
JP5411703B2 (ja) 2006-11-09 2014-02-12 アルコン リサーチ， リミテッド 薬物送達のための水不溶性ポリマーマトリクス
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
CA2678873C (en) 2007-02-19 2016-10-25 Plurogen Therapeutics, Inc. Compositions for treating biofilms and methods for using same
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
CN101317847B (zh) 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
CA2708319A1 (en) 2007-07-27 2009-02-05 The Board Of Trustees Of The Leland Stanford Junior University Supramolecular functionalization of graphitic nanoparticles for drug delivery
CN101129385B (zh) 2007-08-14 2010-07-21 山东博士伦福瑞达制药有限公司 含加替沙星和依碳酸氯替泼诺的眼用组合物及其制备方法
CA2702082A1 (en) 2007-10-08 2009-04-16 Fovea Pharmaceuticals Sa Aqueous ophthalmic formulations
MX2010004366A (es) * 2007-11-05 2010-05-05 Bausch & Lomb Materiales inmiscibles en agua como vehiculos para suministro de farmacos.
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US20090226531A1 (en) 2008-03-07 2009-09-10 Allergan, Inc. Methods and composition for intraocular delivery of therapeutic sirna
US20100008993A1 (en) 2008-07-14 2010-01-14 Proksch Joel W Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs
TWI580441B (zh) 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
WO2010040188A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Biodegradable polymer - bioactive moiety conjugates
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
ES2508290T3 (es) 2009-03-03 2014-10-16 Alcon Research, Ltd. Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
BRPI1014854A2 (pt) 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
EP2335686A1 (en) 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
JP5560719B2 (ja) 2010-01-08 2014-07-30 東レ株式会社 親水性生理活性物質含有微粒子の製造方法
AU2011212941B2 (en) 2010-02-03 2016-03-03 Microbion Corporation Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2011159328A1 (en) 2010-06-16 2011-12-22 Dynavax Technologies Corporation Methods of treatment using tlr7 and/or tlr9 inhibitors
DE102010023949A1 (de) 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US20120252756A1 (en) 2010-06-25 2012-10-04 Coffey Martin J Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
EP2598131A1 (fr) 2010-07-29 2013-06-05 Laboratoires Fournier S.A. Composes pour le traitement/la prevention des maladies inflammatoires oculaires
CN103119030A (zh) 2010-07-30 2013-05-22 兰贝克赛实验室有限公司 基质金属蛋白酶抑制剂
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
US20140148459A1 (en) 2010-09-24 2014-05-29 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
SG188644A1 (en) 2010-09-24 2013-05-31 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
JP2013538821A (ja) 2010-09-24 2013-10-17 ランバクシー ラボラトリーズ リミテッド マトリックスメタロプロテイナーゼ阻害剤
EA201390600A1 (ru) 2010-10-22 2013-09-30 Байнд Терапьютикс, Инк. Терапевтические наночастицы с сополимерами с большим молекулярным весом
AU2011323250B2 (en) 2010-11-05 2015-11-19 The Johns Hopkins University Compositions and methods relating to reduced mucoadhesion
DE102010050570A1 (de) 2010-11-05 2012-05-10 F. Holzer Gmbh Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
KR101813482B1 (ko) 2010-11-24 2017-12-29 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 루푸스의 치료 또는 예방을 위한 조성물 및 방법
WO2012074980A2 (en) 2010-12-01 2012-06-07 Dara Biosciences, Inc. Methods of treating or preventing autoimmune disorders and liver disorders using indane acetic acid derivatives
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
WO2012088431A1 (en) 2010-12-23 2012-06-28 Ironwood Pharmaceuticals, Inc. Faah inhibitors
US20140024627A1 (en) 2011-01-03 2014-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
WO2012149228A1 (en) 2011-04-26 2012-11-01 Genentech, Inc. Compositions and method for treating autoimmune diseases
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis
MX360666B (es) 2011-05-12 2018-11-13 Foresight Biotherapeutics Inc Composiciones de yodopovidona estables con antiinflamatorios esteroides y no esteroides.
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
CN102311395B (zh) 2011-07-05 2014-04-16 张爱华 喹唑啉环取代的二苯脲类衍生物及其用途
US8859525B2 (en) 2011-07-19 2014-10-14 Bausch & Lomb Incorporated Pharmaceutical compositions comprising mushroom-based polysaccharides and uses thereof
TW201808311A (zh) 2011-09-16 2018-03-16 遠景生物製藥股份有限公司 安定之普維酮-碘組成物
WO2013061269A1 (en) 2011-10-26 2013-05-02 Micro Labs Limited Combinations of loteprednol and olopatadine for the treatment of ocular allergies
WO2013065029A1 (en) 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing moxifloxacin and prednisolone for treatment of ocular infections
CA2859046C (en) 2011-12-14 2019-10-22 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
US20130217657A1 (en) 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions
WO2013098615A1 (en) 2011-12-27 2013-07-04 Dh Technologies Development Pte. Ltd. High voltage power supply filter
US9415020B2 (en) 2012-01-19 2016-08-16 The Johns Hopkins University Nanoparticle formulations with enhanced mucosal penetration
US9278132B2 (en) 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
US8962577B2 (en) 2012-03-16 2015-02-24 The Johns Hopkins University Controlled release formulations for the delivery of HIF-1 inhibitors
US20140107025A1 (en) 2012-04-16 2014-04-17 Jade Therapeutics, Llc Ocular drug delivery system
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
CN111700878A (zh) 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US9827191B2 (en) * 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US10864219B2 (en) * 2012-05-03 2020-12-15 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
BR112015005878A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
AU2013317899A1 (en) 2012-09-20 2015-05-07 Akina, Inc. Biodegradable microcapsules containing filling material
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
WO2014165308A2 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
US20140378401A1 (en) 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
KR20160099084A (ko) * 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도

Also Published As

Publication number Publication date
US20180280290A1 (en) 2018-10-04
AU2014342097B2 (en) 2017-09-07
CN105916509B (zh) 2020-07-17
US20180256497A1 (en) 2018-09-13
US20200368155A1 (en) 2020-11-26
US10646437B2 (en) 2020-05-12
EP3062796A1 (en) 2016-09-07
US9827191B2 (en) 2017-11-28
US20200297624A1 (en) 2020-09-24
US10646436B2 (en) 2020-05-12
US20180064641A1 (en) 2018-03-08
US10940108B2 (en) 2021-03-09
CN111743878B (zh) 2023-04-11
CA2928969C (en) 2021-11-30
MX2016005710A (es) 2017-02-08
AU2014342097A1 (en) 2016-05-12
CA2928969A1 (en) 2015-05-07
US20150125539A1 (en) 2015-05-07
MX2021007794A (es) 2021-08-11
US20160228358A9 (en) 2016-08-11
CN111743879A (zh) 2020-10-09
JP6978096B2 (ja) 2021-12-08
US10993908B2 (en) 2021-05-04
US10857096B2 (en) 2020-12-08
WO2015066444A1 (en) 2015-05-07
US20200368154A1 (en) 2020-11-26
JP6751669B2 (ja) 2020-09-09
JP7368661B2 (ja) 2023-10-25
US10688045B2 (en) 2020-06-23
CN111743878A (zh) 2020-10-09
EP3062796B1 (en) 2026-07-08
JP2016535777A (ja) 2016-11-17
JP2022009979A (ja) 2022-01-14
CA3135978A1 (en) 2015-05-07
CN105916509A (zh) 2016-08-31
US10945948B2 (en) 2021-03-16
EP3062796A4 (en) 2017-05-03
US20200289409A1 (en) 2020-09-17
JP2020050663A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
HK1208161A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
IN2013MU03583A (enExample)
HK1208162A1 (en) Pharmaceutical nanoparticles showing improved mucosal transport
EA201891147A1 (ru) Агрегирующие микрочастицы для лекарственной терапии
PE20170312A1 (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso
WO2014153009A3 (en) Thiosaccharide mucolytic agents
PH12014502571B1 (en) Ophthalmic compositions with improved dessication protection and retention
MX2016005764A (es) Formulacion en suspension acuosa que comprende nanoparticulas de antibioticos macrolidos.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
MX383792B (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2016015208A (es) Nanoparticulas de clevidipina y composiciones farmaceuticas que las contienen.
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
MX391574B (es) Partículas coloidales para su uso en medicina.
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
HK1226333A1 (en) Compositions and methods for ophthalmic and/or other applications
MX2014009573A (es) Composicion farmaceutica acuosa con estabilidad mejorada.
IN2014MU00284A (enExample)
NZ733080A (en) Pharmaceutical nanoparticles showing improved mucosal transport
MX2016002620A (es) Formulacion de farmaco novedoso.
GR1008332B (el) Συνθεσεις νανοφορεων
GR1008261B (el) Συνθεσεις νανοφορεων
EA201690113A1 (ru) Везикулы